Skip to main content

Table 1 Demographic data and clinical characteristics of patients with non-cirrhotic NAFLD and cirrhotic NAFLD

From: Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study

  Non-cirrhotic NAFLD
n (%)
Cirrhotic NAFLD
n (%)
P value
Total 367,690 (100) 25,110 (100)  
Gender    < 0.001
 Male gender 153,250 (41.7) 9380 (37.4)  
 Female gender 214,440 (58.3) 15,730 (62.6)  
Age group    < 0.001
 Age > 65 years 126,100 (34.3) 13,860 (55.2)  
 Age 18–65 years 241,590 (65.7) 11,250 (44.8)  
Race    < 0.001
 Non-Hispanic white 303,750 (82.6) 21,910 (87.3)  
 Non-Hispanic black 31,510 (8.6) 1240 (4.9)  
 Hispanic 6260 (1.7) 560 (2.2)  
 Others/unknown 26,170 (7.1) 1400 (5.6)  
Comorbidities    
 Obesity 187,820 (51.1) 13,810 (55.0) < 0.001
 Morbid obesity 91,790 (25.0) 7560 (30.1) < 0.001
 Diabetes mellitus 154,710 (42.1) 16,860 (67.1) < 0.001
 Hypertension 255,190 (69.4) 20,120 (80.1) < 0.001
 Hyperlipidemia 256,880 (69.9) 17,480 (69.6) 0.405
Smoker 54,870 (14.9) 5310 (21.1) < 0.001
Laboratory data    
 High ALT 166,910 (45.4) 13,250 (52.8) < 0.001
Medication use    
 Statin 177,160 (48.2) 13,060 (52.0) < 0.001
 ACEI or ARBs 197,440 (53.7) 15,950 (63.5) < 0.001
 Metformin 113,480 (30.9) 10,550 (42.0) < 0.001
 Sulfonylurea 50,940 (13.9) 6420 (25.6) < 0.001
 Thiazolidinedione 16,170 (4.4) 1890 (7.5) < 0.001
 Insulin 82,900 (22.6) 12,530 (49.9) < 0.001
Liver decompensation 14,690 (58.5)  
 Variceal bleeding 1590 (6.3)  
 Hepatic encephalopathy 3830 (15.3)  
 Ascites 7420 (29.6)  
 Elevated bilirubin 10,130 (40.3)  
HCC 170 (0.000462) 940 (0.037435) < 0.001
  1. ACEI angiotensin converting enzyme inhibitor, ALT alanine aminotransferases, ARBs angiotensin ii receptor blocker, HCC hepatocellular carcinoma, NAFLD non-alcoholic fatty liver disease